Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.
3 Medical Stocks With Solid Growth Drivers to Keep Track Of
by Indrajit Bandyopadhyay
Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.
FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids
by Zacks Equity Research
Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.
Company News for Dec 9, 2022
by Zacks Equity Research
Companies in The News Are: COP, NVDA, MRNA, RENT
Company News for Dec 8, 2022
by Zacks Equity Research
Companies in The News Are: UAL, BKNG, MRNA, CVNA
Bucking the Trend: 3 Stocks Showing Stellar Relative Strength this Week
by Andrew Rocco
Market pullbacks can offer a treasure trove of ideas in the form of relative strength.
Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.
Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
by Shaun Pruitt
Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.
Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL
by Zacks Equity Research
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.
Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why
by Zacks Equity Research
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI
by Zacks Equity Research
Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.
Buy this Medical Sector Pioneer Stock
by Shaun Pruitt
Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen
by Zacks Equity Research
Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
by Zacks Equity Research
Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.
Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal
by Zacks Equity Research
Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.
Company News for Nov 15, 2022
by Zacks Equity Research
Companies in The News Are: MSFT, MRNA, BBWI, TSN
Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update
by Zacks Equity Research
Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.
Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook
by Zacks Equity Research
Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
by Zacks Equity Research
Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
Moderna (MRNA) Lags Q3 Earnings Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Alkermes (ALKS) Q3 Earnings Match Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.